<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02550288</url>
  </required_header>
  <id_info>
    <org_study_id>0653C-383</org_study_id>
    <secondary_id>153060</secondary_id>
    <nct_id>NCT02550288</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)</brief_title>
  <official_title>A Phase III, Randomized, Active Comparator-controlled Clinical Trial to Study the Efficacy and Safety of MK-0653C in Japanese Patients With Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of MK-0653C (Ezetimibe [EZ] 10
      mg/Atorvastatin [Atora] 10mg or 20 mg) compared to EZ 10 mg, Atora 10 mg, or Atora 20 mg
      alone when administered to Japanese participants with hypercholesterolemia. The primary
      hypothesis is that MK-0653C (EZ 10 mg/Atorva 10 mg) is superior to EZ 10 mg and is superior
      to Atorva 10 mg and that MK-0653C (EZ 10 mg/Atorva 20 mg) is superior to EZ 10 mg and is
      superior to Atorva 20 mg in percent change from baseline in low-density lipoprotein
      cholesterol (LDL-C) after 12 weeks of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 29, 2015</start_date>
  <completion_date type="Actual">May 30, 2016</completion_date>
  <primary_completion_date type="Actual">May 30, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Participants had LDL-C levels assessed at baseline and after 12 weeks of study drug administration. The change from baseline was calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience 1 or More Gastrointestinal-related Adverse Events (AEs)</measure>
    <time_frame>up to 14 weeks</time_frame>
    <description>Gastrointestinal-related AEs included all preferred terms within system organ class of Gastrointestinal Disorders except Chapped Lips and Toothache.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience 1 or More Gallbladder-related AEs</measure>
    <time_frame>up to 14 weeks</time_frame>
    <description>Gallbladder-related AEs included Bile Duct Obstruction, Bile Duct Stone, Bile Duct Stenosis, Biliary Colic, Cholangitis, Cholecystectomy, Cholecystitis, Cholelithiasis, Gallbladder Disorder, Gallbladder Perforation, Hepatic Pain, and Hydrocholecystis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience 1 or More Allergic Reaction or Rash AEs</measure>
    <time_frame>up to 14 weeks</time_frame>
    <description>Allergic Reaction or Rash AEs included Allergy to Arthropod Sting, Anaphylactoid Reaction, Anaphylactic Reaction, Anaphylatic Shock, Anaphylactoid Shock, Angioedema, Conjunctivitis Allergic, Contrast Media Reaction, Dermatitis, Dermatitis Allergic, Dermatitis Atopic, Dermatitis Bullous, Dermatitis Contact, Dermatitis Psoriasiform, Drug Hypersensitivity, Eczema, Eosinophila, Erythema, Eye Allergy, Face Oedema, Hypersensitivity, Mechanical Urticaria, Palmar Erythema, Periorbital Oedema, Photodermatosis, Photosensitivity Allergic reaction, Photosensitivity Reaction, Pigmentation Disorder, Pruritus, Pruritus Generalised, Rash, Rash Erythematous, Rash Follicular, Rash Generalised, Rash Maculo-Papular, Rash Papulosquamous, Rash Pruritic, Rash Pustular, Rash Vesicular, Rhinitis, Rhinitis Allergic, Rosacea, Skin Exfoliation, Skin Disorder, Skin Hyperpigmentation, Skin Lesion, Skin Mass, Skin Ulcer, Subcutaneous Nodule, Swelling Face, Systemic Lupus Erythematosus Rash, Urticaria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience 1 or More Hepatitis-related AEs</measure>
    <time_frame>up to 14 weeks</time_frame>
    <description>Hepatitis-related AEs included Cholestasis, Cytolytic Hepatitis, Hepatic Cyst, Hepatic Failure, Hepatic Lesion, Hepatic Necrosis, Hepatitis, Hepatitis Cholestatic, Hepatitis Fulminant, Hepatitis Infectious, Hepatocellular Injury, Hepatomegaly, Jaundice, Jaundice Cholestatic.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) ≥3 Times Upper Limit of Normal (ULN)</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Participants had ALT levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of ALT that were 3 x ULN or greater were recorded. The ALT ULN was 40 U/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience Consecutive Elevations in Aspartate Aminotransferase (AST) ≥3 Times ULN</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Participants had AST levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of AST that were 3 x ULN or greater were recorded. The AST ULN was 40 U/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience Consecutive Elevations in ALT and/or AST ≥3 Times ULN</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Participants had ALT and AST levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of ALT and/or AST that were 3 x ULN or greater were recorded. The ALT and AST ULNs were 40 U/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience Consecutive Elevations in ALT ≥5 Times ULN</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Participants had ALT levels assessed throughout the 12 week treatment period. Participants who had an assessment of ALT that was 5x ULN or greater were recorded. The ALT ULN was 40 U/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience Consecutive Elevations in AST ≥5 Times ULN</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Participants had AST levels assessed throughout the 12 week treatment period. Participants who had an assessment of AST that was 5x ULN or greater were recorded. AST ULN was 40 U/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Have Consecutive Elevations in ALT and/or AST ≥5 Times ULN</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Participants had ALT and AST levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of ALT and/or AST that were 5 x ULN or greater were recorded. The ALT and AST ULNs were 40 U/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience Consecutive Elevations in ALT ≥10 Times ULN</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Participants had ALT levels assessed throughout the 12 week treatment period. Participants who had an assessment of ALT that was 10x ULN or greater were recorded. The ALT ULN was 40 U/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience Consecutive Elevations in AST ≥10 Times ULN</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Participants had AST levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of AST that were 10x ULN or greater were recorded. The AST ULN was 40 U/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Have Consecutive Elevations in ALT and/or AST ≥10 Times ULN</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Participants had ALT and AST levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of ALT and/or AST that were 10x ULN or greater were recorded. The ALT and AST ULNs were 40 U/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Potential Hy's Law Condition</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Percentage of Participants with Potential Hy's Law Condition (defined as serum ALT or serum AST elevations &gt;3xULN, with serum alkaline phosphatase &lt;2xULN and total bilirubin (TBL) ≥2xULN) was summarized. The ALT and AST ULNs were 40 U/L. The ULN for alkaline phosphatase was 359 IU/L and the ULN for total bilirubin was 1.2 mg/dL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Have Elevations in Creatine Kinase (CK) ≥10xULN</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Participants had creatine phosphokinase (CK) levels assessed throughout the 12 week treatment period. Participants who had any CK level that was ≥10 x ULN were recorded. The CK ULNs for males and females were 287 IU/L and 163 IU/L, respectively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Have Elevations in CK ≥10xULN With Muscle Symptoms</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Participants had CK levels assessed throughout the 12 week treatment period. Participants who had any CK level that was ≥10 x ULN and had associated muscle symptoms present within +/- 7 days were recorded. The CK ULNs for males and females were 287 IU/L and 163 IU/L, respectively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Have Elevations in CK ≥10xULN and Drug-Related Muscle Symptoms</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Participants had CK levels assessed throughout the 12 week treatment period. Participants who had any CK level that was ≥10 x ULN and had associated muscle symptoms present within +/- 7 days that were reported as at least possibly-related to study drug were recorded. The CK ULNs for males and females were 287 IU/L and 163 IU/L, respectively.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">309</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Ezetimibe 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe 10 mg + Atorvastatin 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe 10 mg + Atorvastatin 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe 10 mg</intervention_name>
    <arm_group_label>Ezetimibe 10 mg</arm_group_label>
    <arm_group_label>Ezetimibe 10 mg + Atorvastatin 10 mg</arm_group_label>
    <arm_group_label>Ezetimibe 10 mg + Atorvastatin 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 10 mg</intervention_name>
    <arm_group_label>Atorvastatin 10 mg</arm_group_label>
    <arm_group_label>Atorvastatin 20 mg</arm_group_label>
    <arm_group_label>Ezetimibe 10 mg + Atorvastatin 10 mg</arm_group_label>
    <arm_group_label>Ezetimibe 10 mg + Atorvastatin 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Ezetimibe 10 mg tablet</intervention_name>
    <arm_group_label>Atorvastatin 10 mg</arm_group_label>
    <arm_group_label>Atorvastatin 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Atorvastatin 10 mg capsule</intervention_name>
    <arm_group_label>Ezetimibe 10 mg</arm_group_label>
    <arm_group_label>Atorvastatin 10 mg</arm_group_label>
    <arm_group_label>Ezetimibe 10 mg + Atorvastatin 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Diet control/Daily Exercise</intervention_name>
    <description>Diet and Daily exercise program as per Japan Atherosclerosis Society Guideline 2012 (JAS2012)</description>
    <arm_group_label>Ezetimibe 10 mg</arm_group_label>
    <arm_group_label>Atorvastatin 10 mg</arm_group_label>
    <arm_group_label>Atorvastatin 20 mg</arm_group_label>
    <arm_group_label>Ezetimibe 10 mg + Atorvastatin 10 mg</arm_group_label>
    <arm_group_label>Ezetimibe 10 mg + Atorvastatin 20 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese outpatient with hypercholesterolemia.

          -  Females must be non-reproductive potential or agree to remain abstinent or use (or
             partner use) two acceptable methods of birth control from date of signed informed
             consent to the 14 days after the last dose of study drug

          -  Agree to maintain a stable diet that is consistent with the Japan Atherosclerosis
             Society Guideline 2012 (JAS2012) for prevention of atherosclerotic cardiovascular
             diseases for the duration of the study

        Exclusion Criteria:

          -  Uncontrolled hypertension

          -  Type 1 or uncontrolled type 2 diabetes mellitus (treated or untreated)

          -  History of coronary artery disease (CAD) Homozygous familial hypercholesterolemia or
             has undergone LDL apheresis

          -  Had a gastrointestinal tract bypass, or other significant intestinal malabsorption

          -  History of cancer within the past 5 years except for successfully treated
             dermatological basal cell or squamous cell carcinoma or in situ cervical cancer

          -  Human immunodeficiency virus (HIV) positive

          -  History of drug/ alcohol abuse within the past 5 years or psychiatric illness not
             adequately controlled and stable on pharmacotherapy

          -  Consumes more than 25 g of alcohol per day

          -  Consumes more than 1L of grapefruit juice per day

          -  Currently following an excessive weight reduction diet

          -  Engaging in a vigorous exercise regimen (e.g.; marathon training, body building
             training etc.) or intends to start training during the study

          -  Hypersensitivity or intolerance to ezetimibe or atorvastatin

          -  History of myopathy or rhabdomyolysis with ezetimibe or any statin

          -  Pregnant or lactating

          -  Taking any other investigational drugs and/or has taken any investigational drugs
             within 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <results_reference>
    <citation>Teramoto T, Yokote K, Nishida C, Tershakovec AM, Oshima N, Takase T, Hirano T, Lee R, Johnson-Levonas AO. A phase III, clinical trial to study the efficacy and tolerability of ezetimibe plus atorvastatin combination therapy in Japanese patients with hypercholesterolemia: a randomized, double-blind comparative study. J Clin Therapeut Med. 2017;33(7):551-567</citation>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2015</study_first_submitted>
  <study_first_submitted_qc>September 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2015</study_first_posted>
  <results_first_submitted>May 24, 2017</results_first_submitted>
  <results_first_submitted_qc>May 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 21, 2017</results_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Study consisted of screening, a 2-week placebo run-in and a 12-week treatment period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ezetimibe 10 mg</title>
          <description>1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Atorvastatin 10 mg</title>
          <description>1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Atorvastatin 20 mg</title>
          <description>2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Ezetimibe 10 mg + Atorvastatin 10 mg</title>
          <description>1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks</description>
        </group>
        <group group_id="P5">
          <title>Ezetimibe 10 mg + Atorvastatin 20 mg</title>
          <description>1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="68"/>
                <participants group_id="P3" count="69"/>
                <participants group_id="P4" count="68"/>
                <participants group_id="P5" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="68"/>
                <participants group_id="P4" count="65"/>
                <participants group_id="P5" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant moved</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ezetimibe 10 mg</title>
          <description>1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Atorvastatin 10 mg</title>
          <description>1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Atorvastatin 20 mg</title>
          <description>2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Ezetimibe 10 mg + Atorvastatin 10 mg</title>
          <description>1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks</description>
        </group>
        <group group_id="B5">
          <title>Ezetimibe 10 mg + Atorvastatin 20 mg</title>
          <description>1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="68"/>
            <count group_id="B3" value="69"/>
            <count group_id="B4" value="68"/>
            <count group_id="B5" value="69"/>
            <count group_id="B6" value="309"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.1" spread="9.8"/>
                    <measurement group_id="B2" value="58.9" spread="8.6"/>
                    <measurement group_id="B3" value="58.3" spread="10.3"/>
                    <measurement group_id="B4" value="58.7" spread="10.4"/>
                    <measurement group_id="B5" value="57.9" spread="11.0"/>
                    <measurement group_id="B6" value="58.3" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="37"/>
                    <measurement group_id="B6" value="162"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="32"/>
                    <measurement group_id="B6" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12</title>
        <description>Participants had LDL-C levels assessed at baseline and after 12 weeks of study drug administration. The change from baseline was calculated.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>All participants who received at least 1 dose of study treatment, and had a baseline observation or at least 1 post-baseline observation. One participant who received misallocated study medication during placebo run-in period was excluded from the main population for the analysis of efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe 10 mg</title>
            <description>1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg</title>
            <description>1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 20 mg</title>
            <description>2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe 10 mg + Atorvastatin 10 mg</title>
            <description>1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Ezetimibe 10 mg + Atorvastatin 20 mg</title>
            <description>1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12</title>
          <description>Participants had LDL-C levels assessed at baseline and after 12 weeks of study drug administration. The change from baseline was calculated.</description>
          <population>All participants who received at least 1 dose of study treatment, and had a baseline observation or at least 1 post-baseline observation. One participant who received misallocated study medication during placebo run-in period was excluded from the main population for the analysis of efficacy data.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.3" lower_limit="-22.7" upper_limit="-15.8"/>
                    <measurement group_id="O2" value="-44.0" lower_limit="-46.5" upper_limit="-41.6"/>
                    <measurement group_id="O3" value="-49.1" lower_limit="-51.5" upper_limit="-46.7"/>
                    <measurement group_id="O4" value="-55.6" lower_limit="-58.0" upper_limit="-53.2"/>
                    <measurement group_id="O5" value="-59.2" lower_limit="-61.6" upper_limit="-56.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-36.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.5</ci_lower_limit>
            <ci_upper_limit>-32.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-11.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.9</ci_lower_limit>
            <ci_upper_limit>-8.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-39.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.1</ci_lower_limit>
            <ci_upper_limit>-35.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-10.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.5</ci_lower_limit>
            <ci_upper_limit>-6.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experience 1 or More Gastrointestinal-related Adverse Events (AEs)</title>
        <description>Gastrointestinal-related AEs included all preferred terms within system organ class of Gastrointestinal Disorders except Chapped Lips and Toothache.</description>
        <time_frame>up to 14 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe 10 mg</title>
            <description>1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg</title>
            <description>1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 20 mg</title>
            <description>2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe 10 mg + Atorvastatin 10 mg</title>
            <description>1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Ezetimibe 10 mg + Atorvastatin 20 mg</title>
            <description>1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experience 1 or More Gastrointestinal-related Adverse Events (AEs)</title>
          <description>Gastrointestinal-related AEs included all preferred terms within system organ class of Gastrointestinal Disorders except Chapped Lips and Toothache.</description>
          <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="8.7"/>
                    <measurement group_id="O4" value="7.4"/>
                    <measurement group_id="O5" value="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experience 1 or More Gallbladder-related AEs</title>
        <description>Gallbladder-related AEs included Bile Duct Obstruction, Bile Duct Stone, Bile Duct Stenosis, Biliary Colic, Cholangitis, Cholecystectomy, Cholecystitis, Cholelithiasis, Gallbladder Disorder, Gallbladder Perforation, Hepatic Pain, and Hydrocholecystis.</description>
        <time_frame>up to 14 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe 10 mg</title>
            <description>1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg</title>
            <description>1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 20 mg</title>
            <description>2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe 10 mg + Atorvastatin 10 mg</title>
            <description>1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Ezetimibe 10 mg + Atorvastatin 20 mg</title>
            <description>1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experience 1 or More Gallbladder-related AEs</title>
          <description>Gallbladder-related AEs included Bile Duct Obstruction, Bile Duct Stone, Bile Duct Stenosis, Biliary Colic, Cholangitis, Cholecystectomy, Cholecystitis, Cholelithiasis, Gallbladder Disorder, Gallbladder Perforation, Hepatic Pain, and Hydrocholecystis.</description>
          <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.5"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experience 1 or More Allergic Reaction or Rash AEs</title>
        <description>Allergic Reaction or Rash AEs included Allergy to Arthropod Sting, Anaphylactoid Reaction, Anaphylactic Reaction, Anaphylatic Shock, Anaphylactoid Shock, Angioedema, Conjunctivitis Allergic, Contrast Media Reaction, Dermatitis, Dermatitis Allergic, Dermatitis Atopic, Dermatitis Bullous, Dermatitis Contact, Dermatitis Psoriasiform, Drug Hypersensitivity, Eczema, Eosinophila, Erythema, Eye Allergy, Face Oedema, Hypersensitivity, Mechanical Urticaria, Palmar Erythema, Periorbital Oedema, Photodermatosis, Photosensitivity Allergic reaction, Photosensitivity Reaction, Pigmentation Disorder, Pruritus, Pruritus Generalised, Rash, Rash Erythematous, Rash Follicular, Rash Generalised, Rash Maculo-Papular, Rash Papulosquamous, Rash Pruritic, Rash Pustular, Rash Vesicular, Rhinitis, Rhinitis Allergic, Rosacea, Skin Exfoliation, Skin Disorder, Skin Hyperpigmentation, Skin Lesion, Skin Mass, Skin Ulcer, Subcutaneous Nodule, Swelling Face, Systemic Lupus Erythematosus Rash, Urticaria.</description>
        <time_frame>up to 14 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe 10 mg</title>
            <description>1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg</title>
            <description>1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 20 mg</title>
            <description>2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe 10 mg + Atorvastatin 10 mg</title>
            <description>1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Ezetimibe 10 mg + Atorvastatin 20 mg</title>
            <description>1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experience 1 or More Allergic Reaction or Rash AEs</title>
          <description>Allergic Reaction or Rash AEs included Allergy to Arthropod Sting, Anaphylactoid Reaction, Anaphylactic Reaction, Anaphylatic Shock, Anaphylactoid Shock, Angioedema, Conjunctivitis Allergic, Contrast Media Reaction, Dermatitis, Dermatitis Allergic, Dermatitis Atopic, Dermatitis Bullous, Dermatitis Contact, Dermatitis Psoriasiform, Drug Hypersensitivity, Eczema, Eosinophila, Erythema, Eye Allergy, Face Oedema, Hypersensitivity, Mechanical Urticaria, Palmar Erythema, Periorbital Oedema, Photodermatosis, Photosensitivity Allergic reaction, Photosensitivity Reaction, Pigmentation Disorder, Pruritus, Pruritus Generalised, Rash, Rash Erythematous, Rash Follicular, Rash Generalised, Rash Maculo-Papular, Rash Papulosquamous, Rash Pruritic, Rash Pustular, Rash Vesicular, Rhinitis, Rhinitis Allergic, Rosacea, Skin Exfoliation, Skin Disorder, Skin Hyperpigmentation, Skin Lesion, Skin Mass, Skin Ulcer, Subcutaneous Nodule, Swelling Face, Systemic Lupus Erythematosus Rash, Urticaria.</description>
          <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="2.9"/>
                    <measurement group_id="O3" value="2.9"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experience 1 or More Hepatitis-related AEs</title>
        <description>Hepatitis-related AEs included Cholestasis, Cytolytic Hepatitis, Hepatic Cyst, Hepatic Failure, Hepatic Lesion, Hepatic Necrosis, Hepatitis, Hepatitis Cholestatic, Hepatitis Fulminant, Hepatitis Infectious, Hepatocellular Injury, Hepatomegaly, Jaundice, Jaundice Cholestatic.</description>
        <time_frame>up to 14 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe 10 mg</title>
            <description>1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg</title>
            <description>1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 20 mg</title>
            <description>2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe 10 mg + Atorvastatin 10 mg</title>
            <description>1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Ezetimibe 10 mg + Atorvastatin 20 mg</title>
            <description>1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experience 1 or More Hepatitis-related AEs</title>
          <description>Hepatitis-related AEs included Cholestasis, Cytolytic Hepatitis, Hepatic Cyst, Hepatic Failure, Hepatic Lesion, Hepatic Necrosis, Hepatitis, Hepatitis Cholestatic, Hepatitis Fulminant, Hepatitis Infectious, Hepatocellular Injury, Hepatomegaly, Jaundice, Jaundice Cholestatic.</description>
          <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) ≥3 Times Upper Limit of Normal (ULN)</title>
        <description>Participants had ALT levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of ALT that were 3 x ULN or greater were recorded. The ALT ULN was 40 U/L.</description>
        <time_frame>up to 12 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe 10 mg</title>
            <description>1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg</title>
            <description>1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 20 mg</title>
            <description>2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe 10 mg + Atorvastatin 10 mg</title>
            <description>1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Ezetimibe 10 mg + Atorvastatin 20 mg</title>
            <description>1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) ≥3 Times Upper Limit of Normal (ULN)</title>
          <description>Participants had ALT levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of ALT that were 3 x ULN or greater were recorded. The ALT ULN was 40 U/L.</description>
          <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="1.5"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experience Consecutive Elevations in Aspartate Aminotransferase (AST) ≥3 Times ULN</title>
        <description>Participants had AST levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of AST that were 3 x ULN or greater were recorded. The AST ULN was 40 U/L.</description>
        <time_frame>up to 12 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe 10 mg</title>
            <description>1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg</title>
            <description>1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 20 mg</title>
            <description>2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe 10 mg + Atorvastatin 10 mg</title>
            <description>1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Ezetimibe 10 mg + Atorvastatin 20 mg</title>
            <description>1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experience Consecutive Elevations in Aspartate Aminotransferase (AST) ≥3 Times ULN</title>
          <description>Participants had AST levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of AST that were 3 x ULN or greater were recorded. The AST ULN was 40 U/L.</description>
          <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="1.5"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experience Consecutive Elevations in ALT and/or AST ≥3 Times ULN</title>
        <description>Participants had ALT and AST levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of ALT and/or AST that were 3 x ULN or greater were recorded. The ALT and AST ULNs were 40 U/L.</description>
        <time_frame>up to 12 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe 10 mg</title>
            <description>1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg</title>
            <description>1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 20 mg</title>
            <description>2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe 10 mg + Atorvastatin 10 mg</title>
            <description>1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Ezetimibe 10 mg + Atorvastatin 20 mg</title>
            <description>1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experience Consecutive Elevations in ALT and/or AST ≥3 Times ULN</title>
          <description>Participants had ALT and AST levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of ALT and/or AST that were 3 x ULN or greater were recorded. The ALT and AST ULNs were 40 U/L.</description>
          <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="1.5"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experience Consecutive Elevations in ALT ≥5 Times ULN</title>
        <description>Participants had ALT levels assessed throughout the 12 week treatment period. Participants who had an assessment of ALT that was 5x ULN or greater were recorded. The ALT ULN was 40 U/L.</description>
        <time_frame>up to 12 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe 10 mg</title>
            <description>1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg</title>
            <description>1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 20 mg</title>
            <description>2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe 10 mg + Atorvastatin 10 mg</title>
            <description>1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Ezetimibe 10 mg + Atorvastatin 20 mg</title>
            <description>1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experience Consecutive Elevations in ALT ≥5 Times ULN</title>
          <description>Participants had ALT levels assessed throughout the 12 week treatment period. Participants who had an assessment of ALT that was 5x ULN or greater were recorded. The ALT ULN was 40 U/L.</description>
          <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="1.5"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experience Consecutive Elevations in AST ≥5 Times ULN</title>
        <description>Participants had AST levels assessed throughout the 12 week treatment period. Participants who had an assessment of AST that was 5x ULN or greater were recorded. AST ULN was 40 U/L.</description>
        <time_frame>up to 12 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe 10 mg</title>
            <description>1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg</title>
            <description>1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 20 mg</title>
            <description>2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe 10 mg + Atorvastatin 10 mg</title>
            <description>1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Ezetimibe 10 mg + Atorvastatin 20 mg</title>
            <description>1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experience Consecutive Elevations in AST ≥5 Times ULN</title>
          <description>Participants had AST levels assessed throughout the 12 week treatment period. Participants who had an assessment of AST that was 5x ULN or greater were recorded. AST ULN was 40 U/L.</description>
          <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="1.5"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Have Consecutive Elevations in ALT and/or AST ≥5 Times ULN</title>
        <description>Participants had ALT and AST levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of ALT and/or AST that were 5 x ULN or greater were recorded. The ALT and AST ULNs were 40 U/L.</description>
        <time_frame>up to 12 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe 10 mg</title>
            <description>1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg</title>
            <description>1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 20 mg</title>
            <description>2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe 10 mg + Atorvastatin 10 mg</title>
            <description>1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Ezetimibe 10 mg + Atorvastatin 20 mg</title>
            <description>1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Have Consecutive Elevations in ALT and/or AST ≥5 Times ULN</title>
          <description>Participants had ALT and AST levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of ALT and/or AST that were 5 x ULN or greater were recorded. The ALT and AST ULNs were 40 U/L.</description>
          <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="1.5"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experience Consecutive Elevations in ALT ≥10 Times ULN</title>
        <description>Participants had ALT levels assessed throughout the 12 week treatment period. Participants who had an assessment of ALT that was 10x ULN or greater were recorded. The ALT ULN was 40 U/L.</description>
        <time_frame>up to 12 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe 10 mg</title>
            <description>1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg</title>
            <description>1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 20 mg</title>
            <description>2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe 10 mg + Atorvastatin 10 mg</title>
            <description>1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Ezetimibe 10 mg + Atorvastatin 20 mg</title>
            <description>1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experience Consecutive Elevations in ALT ≥10 Times ULN</title>
          <description>Participants had ALT levels assessed throughout the 12 week treatment period. Participants who had an assessment of ALT that was 10x ULN or greater were recorded. The ALT ULN was 40 U/L.</description>
          <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experience Consecutive Elevations in AST ≥10 Times ULN</title>
        <description>Participants had AST levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of AST that were 10x ULN or greater were recorded. The AST ULN was 40 U/L.</description>
        <time_frame>up to 12 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe 10 mg</title>
            <description>1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg</title>
            <description>1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 20 mg</title>
            <description>2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe 10 mg + Atorvastatin 10 mg</title>
            <description>1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Ezetimibe 10 mg + Atorvastatin 20 mg</title>
            <description>1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experience Consecutive Elevations in AST ≥10 Times ULN</title>
          <description>Participants had AST levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of AST that were 10x ULN or greater were recorded. The AST ULN was 40 U/L.</description>
          <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="1.5"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Have Consecutive Elevations in ALT and/or AST ≥10 Times ULN</title>
        <description>Participants had ALT and AST levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of ALT and/or AST that were 10x ULN or greater were recorded. The ALT and AST ULNs were 40 U/L.</description>
        <time_frame>up to 12 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe 10 mg</title>
            <description>1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg</title>
            <description>1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 20 mg</title>
            <description>2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe 10 mg + Atorvastatin 10 mg</title>
            <description>1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Ezetimibe 10 mg + Atorvastatin 20 mg</title>
            <description>1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Have Consecutive Elevations in ALT and/or AST ≥10 Times ULN</title>
          <description>Participants had ALT and AST levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of ALT and/or AST that were 10x ULN or greater were recorded. The ALT and AST ULNs were 40 U/L.</description>
          <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="1.5"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Potential Hy's Law Condition</title>
        <description>Percentage of Participants with Potential Hy's Law Condition (defined as serum ALT or serum AST elevations &gt;3xULN, with serum alkaline phosphatase &lt;2xULN and total bilirubin (TBL) ≥2xULN) was summarized. The ALT and AST ULNs were 40 U/L. The ULN for alkaline phosphatase was 359 IU/L and the ULN for total bilirubin was 1.2 mg/dL.</description>
        <time_frame>up to 12 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe 10 mg</title>
            <description>1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg</title>
            <description>1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 20 mg</title>
            <description>2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe 10 mg + Atorvastatin 10 mg</title>
            <description>1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Ezetimibe 10 mg + Atorvastatin 20 mg</title>
            <description>1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Potential Hy's Law Condition</title>
          <description>Percentage of Participants with Potential Hy's Law Condition (defined as serum ALT or serum AST elevations &gt;3xULN, with serum alkaline phosphatase &lt;2xULN and total bilirubin (TBL) ≥2xULN) was summarized. The ALT and AST ULNs were 40 U/L. The ULN for alkaline phosphatase was 359 IU/L and the ULN for total bilirubin was 1.2 mg/dL.</description>
          <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Have Elevations in Creatine Kinase (CK) ≥10xULN</title>
        <description>Participants had creatine phosphokinase (CK) levels assessed throughout the 12 week treatment period. Participants who had any CK level that was ≥10 x ULN were recorded. The CK ULNs for males and females were 287 IU/L and 163 IU/L, respectively.</description>
        <time_frame>up to 12 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe 10 mg</title>
            <description>1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg</title>
            <description>1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 20 mg</title>
            <description>2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe 10 mg + Atorvastatin 10 mg</title>
            <description>1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Ezetimibe 10 mg + Atorvastatin 20 mg</title>
            <description>1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Have Elevations in Creatine Kinase (CK) ≥10xULN</title>
          <description>Participants had creatine phosphokinase (CK) levels assessed throughout the 12 week treatment period. Participants who had any CK level that was ≥10 x ULN were recorded. The CK ULNs for males and females were 287 IU/L and 163 IU/L, respectively.</description>
          <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.4"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Have Elevations in CK ≥10xULN With Muscle Symptoms</title>
        <description>Participants had CK levels assessed throughout the 12 week treatment period. Participants who had any CK level that was ≥10 x ULN and had associated muscle symptoms present within +/- 7 days were recorded. The CK ULNs for males and females were 287 IU/L and 163 IU/L, respectively.</description>
        <time_frame>up to 12 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe 10 mg</title>
            <description>1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg</title>
            <description>1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 20 mg</title>
            <description>2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe 10 mg + Atorvastatin 10 mg</title>
            <description>1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Ezetimibe 10 mg + Atorvastatin 20 mg</title>
            <description>1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Have Elevations in CK ≥10xULN With Muscle Symptoms</title>
          <description>Participants had CK levels assessed throughout the 12 week treatment period. Participants who had any CK level that was ≥10 x ULN and had associated muscle symptoms present within +/- 7 days were recorded. The CK ULNs for males and females were 287 IU/L and 163 IU/L, respectively.</description>
          <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Have Elevations in CK ≥10xULN and Drug-Related Muscle Symptoms</title>
        <description>Participants had CK levels assessed throughout the 12 week treatment period. Participants who had any CK level that was ≥10 x ULN and had associated muscle symptoms present within +/- 7 days that were reported as at least possibly-related to study drug were recorded. The CK ULNs for males and females were 287 IU/L and 163 IU/L, respectively.</description>
        <time_frame>up to 12 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe 10 mg</title>
            <description>1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 10 mg</title>
            <description>1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 20 mg</title>
            <description>2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe 10 mg + Atorvastatin 10 mg</title>
            <description>1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Ezetimibe 10 mg + Atorvastatin 20 mg</title>
            <description>1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Have Elevations in CK ≥10xULN and Drug-Related Muscle Symptoms</title>
          <description>Participants had CK levels assessed throughout the 12 week treatment period. Participants who had any CK level that was ≥10 x ULN and had associated muscle symptoms present within +/- 7 days that were reported as at least possibly-related to study drug were recorded. The CK ULNs for males and females were 287 IU/L and 163 IU/L, respectively.</description>
          <population>All randomized participants who received at least 1 dose of actual study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 14 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ezetimibe 10 mg</title>
          <description>1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Atorvastatin 10 mg</title>
          <description>1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Atorvastatin 20 mg</title>
          <description>2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Ezetimibe 10 mg + Atorvastatin 10 mg</title>
          <description>1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks</description>
        </group>
        <group group_id="E5">
          <title>Ezetimibe 10 mg + Atorvastatin 20 mg</title>
          <description>1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E4" events="11" subjects_affected="10" subjects_at_risk="68"/>
                <counts group_id="E5" events="15" subjects_affected="12" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

